These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 29483045)

  • 21. Radical prostatectomy versus watchful waiting in early prostate cancer.
    Bill-Axelson A; Holmberg L; Ruutu M; Garmo H; Stark JR; Busch C; Nordling S; Häggman M; Andersson SO; Bratell S; Spångberg A; Palmgren J; Steineck G; Adami HO; Johansson JE;
    N Engl J Med; 2011 May; 364(18):1708-17. PubMed ID: 21542742
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The cost-effectiveness of active surveillance compared to watchful waiting and radical prostatectomy for low risk localised prostate cancer.
    Lao C; Edlin R; Rouse P; Brown C; Holmes M; Gilling P; Lawrenson R
    BMC Cancer; 2017 Aug; 17(1):529. PubMed ID: 28789623
    [TBL] [Abstract][Full Text] [Related]  

  • 23. What is the optimal definition of misclassification in patients with very low-risk prostate cancer eligible for active surveillance? Results from a multi-institutional series.
    Gandaglia G; Ploussard G; Isbarn H; Suardi N; De Visschere PJ; Futterer JJ; Ghadjar P; Massard C; Ost P; Sooriakumaran P; Surcel CI; van der Bergh RC; Montorsi F; Ficarra V; Giannarini G; Briganti A;
    Urol Oncol; 2015 Apr; 33(4):164.e1-9. PubMed ID: 25620154
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Impact of travel distance to the treatment facility on overall mortality in US patients with prostate cancer.
    Vetterlein MW; Löppenberg B; Karabon P; Dalela D; Jindal T; Sood A; Chun FK; Trinh QD; Menon M; Abdollah F
    Cancer; 2017 Sep; 123(17):3241-3252. PubMed ID: 28472547
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Contemporary Management of Prostate Cancer Patients Suitable for Active Surveillance: A North American Population-based Study.
    Moschini M; Fossati N; Sood A; Lee JK; Sammon J; Sun M; Pucheril D; Dalela D; Montorsi F; Karnes RJ; Briganti A; Trinh QD; Menon M; Abdollah F
    Eur Urol Focus; 2018 Jan; 4(1):68-74. PubMed ID: 28753764
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Population based study of use and determinants of active surveillance and watchful waiting for low and intermediate risk prostate cancer.
    Loeb S; Berglund A; Stattin P
    J Urol; 2013 Nov; 190(5):1742-9. PubMed ID: 23727309
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Long-term health-related quality of life after primary treatment for localized prostate cancer: results from the CaPSURE registry.
    Punnen S; Cowan JE; Chan JM; Carroll PR; Cooperberg MR
    Eur Urol; 2015 Oct; 68(4):600-8. PubMed ID: 25242555
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pathological and biochemical outcomes after radical prostatectomy in men with low-risk prostate cancer meeting the Prostate Cancer International: Active Surveillance criteria.
    Mitsuzuka K; Narita S; Koie T; Kaiho Y; Tsuchiya N; Yoneyama T; Kakoi N; Kawamura S; Tochigi T; Habuchi T; Ohyama C; Arai Y
    BJU Int; 2013 May; 111(6):914-20. PubMed ID: 23320782
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Active treatment in low-risk prostate cancer: a population-based study.
    Roy S; Hyndman ME; Danielson B; Fairey A; Lee-Ying R; Cheung WY; Afzal AR; Xu Y; Abedin T; Quon HC
    Curr Oncol; 2019 Aug; 26(4):e535-e540. PubMed ID: 31548822
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Factors Influencing Selection of Active Surveillance for Localized Prostate Cancer.
    Liu J; Womble PR; Merdan S; Miller DC; Montie JE; Denton BT;
    Urology; 2015 Nov; 86(5):901-5. PubMed ID: 26358397
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Long-Term Outcomes after Deferred Radical Prostatectomy in Men Initially Treated with Active Surveillance.
    Godtman RA; Schafferer M; Pihl CG; Stranne J; Hugosson J
    J Urol; 2018 Oct; 200(4):779-785. PubMed ID: 29730198
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Limitations in Predicting Organ Confined Prostate Cancer in Patients with Gleason Pattern 4 on Biopsy: Implications for Active Surveillance.
    Perlis N; Sayyid R; Evans A; Van Der Kwast T; Toi A; Finelli A; Kulkarni G; Hamilton R; Zlotta AR; Trachtenberg J; Ghai S; Fleshner NE
    J Urol; 2017 Jan; 197(1):75-83. PubMed ID: 27457260
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison of pathological outcomes of active surveillance candidates who underwent radical prostatectomy using contemporary protocols at a high-volume Korean center.
    Lee DH; Jung HB; Lee SH; Rha KH; Choi YD; Hong SJ; Yang SC; Chung BH
    Jpn J Clin Oncol; 2012 Nov; 42(11):1079-85. PubMed ID: 22988037
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Using hospital medical record data to assess the accuracy of the SEER Los Angeles Cancer Surveillance Program for initial treatment of prostate cancer: a small pilot study.
    Kraus RD; Hamilton AS; Carlos M; Ballas LK
    Cancer Causes Control; 2018 Sep; 29(9):815-821. PubMed ID: 30022335
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pathological outcome for Chinese patients with low-risk prostate cancer eligible for active surveillance and undergoing radical prostatectomy: comparison of six different active surveillance protocols.
    Tsang CF; Tsu JH; Lai TC; Wong KW; Ho BS; Ng AT; Ma WK; Yiu MK
    Hong Kong Med J; 2017 Dec; 23(6):609-15. PubMed ID: 29026057
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Long-term quality-of-life outcomes after radical prostatectomy or watchful waiting: the Scandinavian Prostate Cancer Group-4 randomised trial.
    Johansson E; Steineck G; Holmberg L; Johansson JE; Nyberg T; Ruutu M; Bill-Axelson A;
    Lancet Oncol; 2011 Sep; 12(9):891-9. PubMed ID: 21821474
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Validation of Epstein Biopsy Criteria for Insignificant Prostate Cancer in Contemporary Cohort of Croatian Patients.
    Tomasković I; Ulamec M; Tomić M; Pezelj I; Grubisić I; Kruslin B
    Coll Antropol; 2015 Sep; 39(3):709-11. PubMed ID: 26898070
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Use and early mortality outcomes of active surveillance in patients with intermediate-risk prostate cancer.
    Butler SS; Mahal BA; Lamba N; Mossanen M; Martin NE; Mouw KW; Nguyen PL; Muralidhar V
    Cancer; 2019 Sep; 125(18):3164-3171. PubMed ID: 31150125
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Characterization of a "low-risk" cohort of grade group 2 prostate cancer patients: Results from the Shared Equal Access Regional Cancer Hospital database.
    McGinley KF; Sun X; Howard LE; Aronson WJ; Terris MK; Kane CJ; Amling CL; Cooperberg MR; Freedland SJ
    Int J Urol; 2017 Aug; 24(8):611-617. PubMed ID: 28589550
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A 17-Gene Genomic Prostate Score as a Predictor of Adverse Pathology in Men on Active Surveillance.
    Kornberg Z; Cooperberg MR; Cowan JE; Chan JM; Shinohara K; Simko JP; Tenggara I; Carroll PR
    J Urol; 2019 Oct; 202(4):702-709. PubMed ID: 31026214
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.